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The protozoan parasite Toxoplasma gondii is the causative agent of one of the
most widespread parasitic infections of man and is a leading cause of congenital
neurological birth defects and the third most common cause of food-borne
deaths in the United States. Despite this, to date no drugs are available that
provide a fully effective treatment. Recently, the antibacterial agent triclosan
was shown to inhibit the fatty-acid biosynthesis pathway in T. gondii and to
interact with the enoyl reductase (ENR). In order to analyse the potential of
triclosan as a lead compound targeting T. gondii ENR and to explore unique
features of the apicomplexan enzyme that could be exploited in future drug
development, structural studies have been initiated on T. gondii ENR. Crystals
of T. gondii ENR in complex with NAD+ and triclosan were grown using the
hanging-drop vapour-diffusion method with PEG 8000 as precipitant. The
crystals belong to space group P3221, with approximate unit-cell parameters
a = 78.1, b= 78.1, c = 188.5 A˚,  =  = 90,  = 120 and a dimer in the asymmetric
unit. Test data were collected to beyond 2.6 A˚ on cryocooled crystals (100 K)
using a Rigaku MM007 rotating-anode X-ray source, revealing that the crystals
are suitable for a full structural determination.
1. Introduction
Toxoplasma gondii is one of the most widespread infections of man
and warm-blooded animals, infecting an estimated 25% of the world’s
human population (Sibley, 2003). A common transmission route into
humans is through the consumption of undercooked contaminated
meat and the organism is the third most common cause of food-borne
deaths in the United States (Mead et al., 1999). Although commonly
asymptomatic, the parasite can produce severe complications and
may be fatal. One major risk group is patients suffering from immune
suppression, with significant numbers of European and American
patients suffering from Acquired Immunodeficiency Syndrome
(AIDS) dying from toxoplasmosis (Hill & Dubey, 2002). Another
source of severe complications is transmission of T. gondii from
mother to foetus during pregnancy, which can lead to congenital
neurological birth defects (Boyer & McLeod, 2002). Together, the
total health care burden within the USA of toxoplasmosis may be up
to $5 billion per year (Roberts et al., 1994).
A major hurdle in drug delivery to the intracellular T. gondii
parasite is the need for the drug to enter the host cell and to cross a
vacuolar membrane and the plasma membrane of the parasite. In
T. gondii, ENR resides within a plastid organelle surrounded by four
additional membranes. Drug delivery is made even more difficult in
the bradyzoite form of T. gondii, which resides in cysts composed of
parasite and host constituents. In order to address some of these
problems, the common antimicrobial inhibitor triclosan, which has
been shown to target and inhibit T. gondii enoyl-ACP reductase
(TgENR; McLeod et al., 2001), was attached to a releasable octa-
arginine linker and the construct was shown to enhance the effec-
tiveness of triclosan as an antiparasitic agent (Samuel et al., 2003).
The structure of ENR has been solved from Escherichia coli,
Brassica napus, Mycobacterium tuberculosis and Plasmodium falci-
parum. These structures reveal a common architecture reminiscent of
a Rossmann dinucleotide-binding fold, with a parallel -sheet flanked
by -helices (Rossmann et al., 1974). Furthermore, the structure of
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ENR complexed with a range of chemically distinct inhibitors has
revealed key areas of the enzyme that are involved in inhibitor
binding (Roujeinikova et al., 1999; Qiu et al., 1999; Levy et al., 2001;
Miller et al., 2002; Pidugu et al., 2004). Analysis of ENR from
P. falciparum, a close relative of T. gondii, reveals that although the
substrate/inhibitor-binding pocket is similar to those of the plant and
bacterial enzymes, there are distinct differences which could be
exploited for future drug design (Pidugu et al., 2004). Amino-acid
sequence analysis of the ENR enzymes from P. falciparum and
T. gondii shows the presence of a low-complexity hydrophilic insert
ranging in size from 42 to six amino acids, respectively, which is not
mirrored in any plant or bacterial ENR. In order to study the
structural consequences of this insert and to develop ENR as a drug
target for T. gondii therapy, we have initiated a program of rational
drug design on TgENR. In this paper, we report the crystallization
and preliminary X-ray analysis of TgENR complexed with NAD+ and
triclosan.
2. Materials and methods
2.1. Cloning and overexpression
The coding sequence of T. gondii ENR was amplified from cDNA
of the RH strain of T. gondii (Samuel et al., 2003). The 37-mer
forward and reverse primers (forward 50-GGTGGTGAATTCT-
CAAACATAAACAAAATTAAAGAAG-30 and reverse 50-GGT-
GGTGTCGACTTATTCATTTTCATTGCGATATATATC-30) were
used to amplify nucleotides encoding amino-acid residues 103–417 of
TgENR and to introduce a proximal EcoRI and distal SalI site (bold)
into the PCR product. Nucleotides encoding the amino-terminal 102
residues of TgENR were not amplified as they are predicted to
encode a signal peptide and an organellar transit peptide. The
resulting amplicon was digested with EcoRI and SalI and ligated into
the pMALc2x vector (New England Biolabs), which produces a
fusion protein with the maltose-binding protein (MBP) at the amino-
terminus. A second construct of TgENR, also containing residues
103–417, was designed for in vivo cleavage by the TEV (tobacco etch
virus) protease. The amplicon described above was ligated into a
modified version of the pMALc2x vector (pMALcHT) in which the
linker region was altered to contain nucleotides encoding a TEV
protease cleavage site followed by a hexahistidine tag (Muench et al.,
2003). The resulting ligation product, pSTP8, was transformed into
BL21 Star (DE3) cells (Invitrogen) and cotransformed with the pRIL
plasmid from BL21-CodonPlus (DE3) cells (Stratagene) and a
plasmid encoding the TEV protease (Kapust & Waugh, 2000). Cells
were grown in LB medium at 310 K to an optical density at 600 nm of
0.8 and then induced by addition of IPTG to a final concentration of
0.4 mM. The culture was maintained in shaker flasks at 293 K for 12 h
to ensure efficient in vivo cleavage of the fusion protein by TEV
protease and then harvested by centrifugation.
2.2. Purification
Cells were resuspended in lysis buffer [20 mM sodium/potassium
phosphate pH 7.5, 1 mg ml1 lysozyme (Sigma), 2.5 mg ml1 DNAse I
(Sigma), 20 mM NaCl] and sonicated. The cell lysate was clarified by
centrifugation and applied onto a 5 ml HiTrap Chelating HP column
(Amersham Biosciences) equilibrated in 20 mM sodium/potassium
phosphate pH 7.5, 200 mM NaCl for affinity purification. TgENR was
eluted in a linear gradient to 500 mM imidazole at pH 7.5. Column
fractions containing cleaved TgENR were desalted with a HiPrep
26/10 desalting column (Amersham Biosciences) equilibrated in
20 mM Tris pH 7.25 and loaded directly onto a 5 ml HiTrap Q Fast
Flow column (Amersham Biosciences). Bound proteins were eluted
with a linear gradient to 1M NaCl. Column fractions containing
TgENR were pooled and passed through a subtractive 20 ml amylose
column (New England Biolabs) to remove any residual uncut fusion
protein. Pure TgENR fractions were concentrated to 20 mg ml1 for
crystallization trials.
2.3. Crystallization and preliminary X-ray analysis
Initial crystallization trials were carried out at 290 K with Hampton
Research Crystal Screens I and II and PEG/Ion Screen using the
hanging-drop vapour-diffusion technique, mixing 1.5 ml of 10 mg ml1
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Figure 1
A representative 1 oscillation image of data collected from a TgENR–NAD+–triclosan complex crystal using a MAR 345 detector mounted on a Rigaku MM007 generator.
An enlarged view of the region indicated by a square on the diffraction pattern is shown on the right. The edge of the image corresponds to a resolution of 2.4 A˚.
protein solution (20 mM Tris 7.5 and 100 mM NaCl) and an equiva-
lent volume of reservoir solution. Three sets of crystallization trials
were conducted with TgENR in its apo form and in complex with
NAD+ (5 mM) and with NAD+ and triclosan (5 mM NAD+ and 6 mM
triclosan). Of those conditions which produced crystals, the best
quality were those of the TgENR–NAD+–triclosan complex, which
grew in Crystal Screen 1 condition No. 36 (0.1M Tris–HCl pH 8.5 and
8% PEG 8000) and reached dimensions of approximately 0.2 0.2
0.3 mm. Optimization of these conditions led to crystals grown in
0.1M Tris–HCl pH 9.0 with 6% PEG 8000. For preliminary X-ray
analysis, crystals were flash-frozen in 30% glycerol and data were
collected at 100 K using an oscillation width of 1 and an exposure
time of 10 min on a MAR 345 image-plate detector mounted on a
Rigaku MM007 generator. Analysis of the data was carried out using
the DENZO/SCALEPACK package (Otwinowski & Minor, 1997).
3. Results and discussion
In searching for an appropriate cryoprotectant solution for the
crystals of the TgENR–NAD+–triclosan complex, 30% glycerol
produced promising results; however, this produced a significant
increase in mosaicity compared with crystals which were tube-
mounted and analysed at room temperature. In order to overcome
this problem, crystallization trials were conducted in 0.1M Tris–HCl
pH 9.0 with 6% PEG 8000 and the addition of 5, 10, 15, 20 and 30%
glycerol. Crystals of a similar morphology grew in all conditions,
although fewer but larger crystals grew in the presence of greater
than 15% glycerol. The inclusion of 5% glycerol increased crystal
stability during stepwise soaking in 30% glycerol with no significant
increase in crystal mosaicity. However, crystals which grew in higher
levels of glycerol had much reduced diffraction properties. Crystals
grown in the above conditions with an additional 5% glycerol were
flash-frozen in 30% glycerol at 100 K and data were collected using a
rotation oscillation of 1 and an exposure time of 10 min on a
MAR345 image-plate detector mounted on a Rigaku MM007
generator to produce a preliminary data set to 2.6 A˚ (Fig. 1).
Autoindexing and scaling of the data collected were carried out
using DENZO/SCALEPACK (Otwinowski & Minor, 1997) and
preliminary analysis indicated that the crystals belonged to the
trigonal space group P321, with unit-cell parameters a = 78.1, b= 78.1,
c = 188.5 A˚,  =  = 90,  = 120. Analysis of the systematic absences
within the X-ray diffraction pattern revealed the crystals to belong to
space group P3121 or P3221. Data-collection and processing statistics
can be found in Table 1. Analysis of the VM for the TgENR–NAD
+–
triclosan crystals suggests that the asymmetric unit contains a dimer,
with a VM of 2.4 A˚
3 Da1, which is within the range of VM values
observed for protein crystals (Matthews, 1977). Gel-filtration studies
show that TgENR, like the enzyme from other species, is a tetramer
in solution (data not shown) and therefore one of the molecular
twofold axes of the tetramer within the asymmetric unit must be
coincident with a crystallographic twofold axis.
An initial attempt to solve the structure of TgENR by molecular
replacement has been conducted using the programAMoRe (Navaza,
1994) with the coordinates of P. falciparum ENR (unpublished data)
as a search model. The P. falciparum ENR search model was edited
to remove two loop regions of low sequence similarity (between 2
and 3 and between 3 and 3) and then split into the three unique
combinations of the possible dimer in the asymmetric unit. AMoRe
provided a convincing solution in space group P3221, but not in
P3121, suggesting that the former is the correct space group.
Refinement of the structure is currently under way and it is hoped
that this may provide a clear insight into the features of the active site
that are unique to TgENR and which may be exploited in future
drug-development programs.
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Table 1
Data-collection and processing statistics for TgENR–NAD+–triclosan crystals.
Values in parentheses are for the highest resolution shell.
Space group P3221
Wavelength (A˚) 1.54
Resolution (A˚) 30–2.6 (2.69–2.6)
Unique reflections 21105
Multiplicity 5.2
Data completeness (%) 99.9 (99.4)
I/(I) > 3 (%) 74.4 (42.0)
Rmerge† (%) 0.082 (0.48)
† Rmerge =
P
hkl jIi  Imj=
P
hkl Ii , where Ii and Im are the observed intensity and mean
intensity of related reflections, respectively.
